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1. Introduction
Clustered regularly interspaced short palindromic 
repeats (CRISPR) were identified in approximately 
40% of bacterial and approximately 90% of archaeal 
genomes [1]. These loci are usually accompanied by 
conserved sets of genes, encoding nucleic acid process-
ing enzymes like nuclease or helicase proteins, named 
CRISPR-associated (cas) genes. Typically, CRISPR-
Cas loci contain repeats of sequences interspaced by 
spacers with noncoding unique sequences of similar 
lengths [2–5]. The function of CRISPR-Cas as part of 
a defense system against foreign DNA was confirmed in 
2007 [6]. Functionally, the CRISPR-Cas system is based 
on molecular memory of a previous infection, which 
means that during second contact with a bacteriophage 
or other mobile genetic material, the foreign nucleic 
acid is recognized and inactivated.
The CRISPR sequences were previously classified as 
a group of interspaced short sequence repeats (SSRs) 
with a unique structure. Those repeats are interspaced 
by nonrepetitive DNA fragments, which, as was thought 
at the beginning, were not important. These distinct 
inter spaced SSRs were detected for the first time in the 
Escherichia coli K-12 chromosome in 1987 [7]. In subse-
quent years, many scientists have identified this specific 
group of SSRs in many other bacteria, e.g. Streptococcus 
pyogenes, Mycobacterium tuberculosis, Campylobacter 
jejuni, and Clostridium difficile [4, 8, 9]. The function 
of SSRs was unknown and many scientists have named 
the same group of sequences differently. In 2002 Jansen 
et al. [4] used the acronym CRISPR for the first time 
as a name for a characteristic class of repetitive DNA, 
to avoid confusing nomenclature in the future. After 
the discovery of the CRISPR sequence function, the 
CRISPR-Cas designation has become a part of the 
generally accepted nomenclature. Interestingly, before 
recognition of the biological role of CRISPR-Cas, these 
sequences were used as a typing tool in molecular diag-
nostics. The method was established for Yersinia pestis, 
Bacillus anthracis, Salmonella enterica serovar Typhi, 
Francisella tularensis, E. coli O157, and Mycobacterium 
leprae [10]. Currently, scientists have isolated sev-
eral subgroups that differ in the internal structure of 
CRISPR-Cas sequences and associated genes [11–14]. 
In this work we present a brief history of CRISPR-Cas, 
describing the structure and the mechanism of opera-
tion as well as its application on selected examples.
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2. Structure, operation, and differences
The CRISPR-Cas system is based on the involve-
ment of small, noncoding sequences in conjunction 
with Cas proteins. It was found that cas genes are always 
located near a CRISPR locus and the most common 
arrangement of these genes is cas3-cas4-cas1-cas2. The 
Cas3 protein appears to be a helicase, whereas Cas4 
resembles the RecB family of exonucleases and con-
tains a cysteine-rich motif, which suggests DNA bind-
ing properties. Cas1 is generally highly conservative 
and it was found consistently in all species that contain 
CRISPR loci. Repeated sequences in size from 24 to 
48 nucleotides are separated by unique spacers of simi-
lar length. The number of repeated sequences is highly 
variable in bacterial species [11, 15, 16]. 
The classification of CRISPR-Cas systems is com-
plex and still not obvious. However, three basic stages 
of the mechanism of action of the CRISPR-Cas defense 
system are established, namely: a) spacer integration, 
b)  expression of CRISPR locus and cas genes, and 
c) target recognition and neutralization are more or less 
conserved among all CRISPR types and hence can be 
described in general [16]. In this work the CRISPR-Cas 
type II system is used to illustrate in detail this model 
of operation – a clue for developing a CRISPR genome 
editing technique [17, 18]. The first step of this mecha-
nism runs with the integration of short sequences of 
foreign DNA into the CRISPR locus (Fig. 1). Identifi-
cation of foreign DNA begins with recognition of the 
viral protospacer adjacent motif (PAM) via the protein 
complex of two Cas1 dimers and a single Cas2 dimer. 
PAM is a short sequence consisting of 2–8 nucleotides 
and flanking the protospacer, where the Cas1 protein 
is an endonuclease and the Cas2 is an endoribonucle-
ase. These properties allow the Cas1-Cas2 complex to 
cut off the protospacer and integrate with the CRISPR 
array. Before the integration of the new spacer, specific 
enzymes cut the sequence and create its sticky ends. 
This mechanism allows integration of the new spacer 
between the first and second repeats on the leader 
sequence side. During integration, DNA breaks at 
two points, on the 5’ end of the first repeat and next 
on the 5’ end on the opposing side of the repeat. As 
a result, the arisen single-stranded DNA (ssDNA) con-
tains the repeated sequence. In the next step, specific 
enzymes repair gaps in the ssDNA [19]. During the 
expression stage, the CRISPR region with acquired 
foreign sequences is transcribed into a precursor RNA 
transcript and then is cut by the double-stranded RNA-
specific RNase III into specific small RNA molecules 
(crRNAs) [20]. The maturation of crRNA is possible due 
to a small sequence of trans-activating crRNA (tracr-
RNA) (Fig. 1). The tracrRNA is complementary to pre-
Fig. 1. The type II system as an example of mechanism of CRISPR-Cas action-prepared
on the basis of Nishimasu et al. [90] and Amitai et al. [91] .
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crRNA and thus these two molecules form a duplex. 
Each mature crRNA contains a  fragment of a  single 
spacer flanked by part of the repeated sequence [20]. 
In the recognition stage, a complex of crRNA and Cas9 
protein scans the cell for foreign nucleic acid targets. 
This tracing process is ensured by a complementarity 
of crRNA and foreign DNA which allows recognition 
and incorporation of the protein complex. This complex 
contains the Cas9 enzyme which cuts foreign DNA at 
the attachment site and leads to its degradation (Fig. 1) 
[20, 21]. It was shown that deletion or insertion of the 
new spacer sequence complementary to phage genome 
increases or decreases the bacterial sensitivity to phage 
infection, respectively [6].
The first polythetic CRISPR-Cas system classifica-
tion was proposed by Makarova et al. (2011) [5]. In this 
study, CRISPR-Cas systems were differentiated accord-
ing to target molecule and mode of operation. In this 
classification, three major types and 12 subtypes were 
distinguished. Type I and II systems split and degrade 
DNA. The main difference between type I and type II 
systems is the presence of various proteins in the com-
plex, Cas3 and Cas9, respectively. The CRISPR-Cas 
type III contains Cas10 protein and cleaves both DNA 
and RNA [23]. Both type I and II require two princi-
pal factors to effectively target the DNA. The first is 
a  CRISPR RNA spacer complementary to the target 
protospacer sequence. The second is a PAM sequence 
specific to each CRISPR-Cas system. Similar factors 
are required for DNA targeting by type III systems. All 
these systems involve base pairing between the target 
sequence and the region flanking the protospacer [24]. 
The CRISPR-Cas type III system seems to be more ben-
eficial for bacteria because of its various abilities to rec-
ognize and degrade both DNA and RNA. Therefore, it 
is effective against a wider group of phages. Otherwise, 
the type I and type II systems are simpler because of the 
smaller number of Cas proteins engaged. Those mecha-
nisms require less energy from bacteria to transcribe 
and run the mechanism. This may allow for a  faster 
response and defense in case of a phage infection. This 
classification of CRISPR-Cas systems was updated by 
Makarova et al. in 2015 and again in 2020 [13, 25]. The 
fast evolution and major achievements in the study of 
the diversity of the CRISPR-Cas systems lead to the 
creation of its robust classification which is essential to 
understanding their functionality in microorganisms 
and utility as genome-editing tools. Recently, authors 
put special emphasis on the classification of the quickly 
proliferating class 2 variants. In comparison with the 
previous classification system (from 2015), the new 
class  2 includes  3 types (II, V, VI) and 26  subtypes. 
Interestingly, the previous type IIC was divided into 
two extra subtypes (IIC1 and IIC2) and type  V was 
described in detail (17 subtypes were found). Moreover, 
the new type VI was distinguished. The newest clas-
sification is shown in Table I. 
The origin and cause of the system’s mechanism 
diversity are still unexplained. An interesting task now 
would be to determine which of the systems was cre-
ated first, or if they were developed independently of 
each other.
3. Bacterial typing
Primarily, CRISPR sequences have been used as 
a typing tool in epidemiology and phylogenetic stud-
ies. The main elements useful for analysis are the pal-
indromic repeats. The nucleotide sequence, length, 
and loci are highly variable and often strain specific 
among some bacterial species such as M. tuberculosis, 
in which CRISPR-Cas type III-A has been described 
[8, 10, 26, 27]. Due to this, the CRISPR-based approach 
has already been used for the differentiation of many 
bacterial species such as M. tuberculosis [28], C. jejuni 
[29], Corynebacterium diphtheria [30], Legionella pneu-
mophila [31], and E. coli [32]. This CRISPR utility in 
bacterial differentiation may be associated with their 
diverse pathogenicity profile and the unique genetic 
fingerprints of particular strains. Because of their 
unique structure, CRISPR sequences can be used for 
clonal differentiation [33, 34]. As a result of optimiza-
tion, a technique called CRISPR high-resolution melt 
analysis was developed. This method is a combination 
of CRISPR typing with amplified fragment length poly-
morphisms (AFLP) and multilocus sequence typing 
(MLST) [29, 34]. Unfortunately, there are limitations 
for the use of CRISPR typing in phylogenetic studies 
which are based on the evaluation of a number of evolu-
tionary events resulting in sequence changes. For now, 
it is impossible to prove which mutagenic factor could 
be responsible for the loss of a cluster of neighbor-
ing spacers from CRISPR [24, 34]. Data sources 
indicate that the multiplex nature of the CRISPR-
Cas mechanism enables recognition of multiple loci 
simul taneously, which leads to large deletions, inver-
sions, or translocations [35–37]. The system does not 
always require perfect complementarity to target DNA 
sequences, and therefore it is able to cause indel change 
outside the target sequence leading to random muta-
tions [38]. In turn, the stability of CRISPR-Cas in the 
bacterial genome and its mechanism of regulation 
seems to be crucial factors in the process of adaptation 
to unfavorable environmental conditions. 
4. Correlation with bacterial pathogenicity
Presumably, the CRISPR-Cas system acts not only 
as a defense against foreign genetic material, but also 
plays a role in the regulation of other bacterial genes 
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expression [39, 40]. The polymorphism of CRISPR-Cas 
genes in enterohemorrhagic E. coli (EHEC) is associ-
ated with the expression of stx (phage-encoded Shiga 
toxin) and eae (intimin virulence factor) virulence 
genes [41]. It is also confirmed that deletion of genes 
coding for transcription regulators affects the expres-
Table I





Type Subtype Genes included Bacterial species
 I-A cas1, cas2, cas3’, cas3”, cas4, cas5, cas6, cas7, cas8a1, csa5 Archaeoglobus fulgidus
 I-B cas1, cas2, cas3, cas4, cas5, cas6, cas7, cas8b1 Clostridium kluyveri
 I-C cas1, cas2, cas3, cas4, cas5, cas7, cas8c Bacillus halodurans
I I-D cas1, cas2, cas3’, cas3”, cas4, cas6, cas10d, csc1, csc2 Cyanothece sp. 8802
 I-E cas1, cas2, cas3, cas5, cas6, cas7, cse1, cse2 Escherichia coli K-12
 I-F1 cas1, cas2, cas3, cas6f, csy1, csy2,csy3 Yersinia pseudo-tuberculosis
 I-F1 cas1, cas2, cas3, cas6f, csy1, csy2,csy3 Yersinia pseudo-tuberculosis
 I-G cas1, cas2,cas3, cas4, cas5, cas5, cas7, cas8u2 Geobacter sulfurreducens
 III-A cas1, cas2, cas10, cas6, csm2, csm3, csm4, csm5, cms6 Staphylococcus epidermidis
 III-B cas6, cas10, cmr1,cmr3, cmr4, cmr5, cmr6 Pyrococcus furiosus
 III-C cmr1,cmr3, cmr4, cmr5, cmr6, cas10 Methanothermobacter thermautotrophicus
III III-D cas10, cas7, csx10, csm2, csm5, all1473 Synechocystis sp.6803
 III-E TPR+caspase, cas7(3), csm3, csm2, csm5, cas1, cas2,  Candidatus Scalindua brodae
  reverse transcriptase
 III-F cas10, cas5, cas11, csm3 Thermotoga lettingae
 IV-A csf4, csf5, csf1, csf2, csf3, Thioalkalivibrio sp. K90mix
IV IV-B cysH-like, csf1, cas11, csf2, csf3 Rodococcus jostii RHA1
 IV-C large subunit, cas11, csf2, cas5 Thermoflexia bacterium
 II-A cas1,cas2, cas9,csn2, Streptococcus thermophilus
II II-B cas1, cas2,cas4, cas9 Legionella pneumophila str. Paris
 II-C1 cas1, cas2, cas9 Neisseria lactamica, 020-06
 II-C2 cas1, cas2, cas4, cas9 Micrarchaeu acidiphilum ARMAN-1
 V-A cas1, cas2, cas4, cpf1 Francisella cf. novicida Fx1
 V-B1 cas1, cas2, cas4, c2c1 Alicyclobacillus acidoterrestris
 V-B2 cas1, cas2, cas4, cas12b2 Planctomycetes bacterium RBG_13_46_10
 V-C cas1, c2c3 Oleiphilus sp.
 V-D cas1, casY, Bacterium CG09_39_24
 V-E cas1, cas2, cas4, casX Deltaproteobacteria bacterium
 V-F1 cas1, cas2, cas4, cas14a Uncultured archaeon
 V-F1(V-U3) c2c10, Bacillus thuringjensis HD-771
V V-F2 cas1, cas2, cas4, cas14b Uncultured archaeon
 V-F3 cas1, cas2, cas4, cas14c, Candidatus Micrarchaeota archaeon
 V-G cas12g Hot springs metagenome
 V-H cas12h Hypersaline lake sediment metagenome (JGI)
 V-I cas12i Freshwater metagenome (JGI)
 V-K(V-U5) c2c5, tniQ, tnsC, tnsB, Cyanothece sp. PCC8801
 V-U1 c2c4 Gordonia otitidis
 V-U2 c2c8 Cyanothece sp. PCC8801
 V-U4 c2c9 Rothia dentocariosa M567
 VI-A cas1, cas2, c2c2 Leptotrichia shahii
 VI-B1 c2c6, csx28 Previotella buccae
VI VI-B2 csx27, c2c6 Bergeyella zoohelcum
 VI-C c2c7, Fusobacterium perfoetens
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sion of cas genes. For example, removal of the ompR 
regulator in Y. pestis causes changes in expression of 
244 genes, including repression of transcription of cas1 
[42, 43]. It is also very likely that cas genes are involved 
in the bacterial stress response. In Enterococcus faeca-
lis, which causes opportunistic intestinal infections, 
a stress response is mediated by effector molecules, e.g. 
(p)ppGpp. The synthesis of these molecules is regulated 
by pyrophosphokinase GTP, which was correlated 
with the lower expression of cas genes in E. faecalis. 
This observation was described by Yan et al. (2009) 
after antibiotic therapy [44]. García-Gutiérrez et al. 
(2015) showed a  dependency between the increased 
number of virulence factors and the reduced num-
ber of repeated sequences in E. coli CRISPR loci [45]. 
Moreover, it was shown that pathogenic E. coli strains 
isolated from distant ecological niches varied in terms 
of the number of CRISPR repeats. There is also evi-
dence that the CRISPR-Cas regions correlate with 
higher drug resistance of E. coli [46]. It has also been 
noticed that the spacer sequence was complementary 
to plasmids harboring antibiotic resistance genes [80]. 
In another experiment, different biofilm production in 
various E. faecalis strains was observed. The strains that 
possessed CRISPR-Cas systems formed biofilm more 
intensively than bacteria without this system. A similar 
observation was made among Pseudomonas aeruginosa 
PA14, where cas genes affected biofilm production and 
the formation of swarming cells [47–49]. Thus, it can 
be assumed that modification of CRISPR-Cas genes 
may change the profiles of bacterial virulence. It is 
clear that the CRISPR-Cas system is associated with 
modulation of bacterial pathogenicity, including drug 
resistance, but lots of “white spots” still remain an issue 
of CRISPR-Cas biology. An interesting question arises 
whether particular types of the CRISPR-Cas systems 
correlate with the pathogenicity of bacteria or phages? 
5. Potential tool for medicine
5.1. CRISPR-tool for genome editing
Recently, the CRISPR-Cas system has been consid-
ered a tool for genome editing. The ease of use of such 
systems is their main advantage. This is true because of 
the nature of sequence recognition, which differs sig-
nificantly from conventional, nuclease-mediated DNA 
editing techniques. The advantage of the CRISPR-Cas 
results from the fact that DNA recognition comes not 
from protein but from the 20-bp guide RNA sequence 
[50]. Instead of preparation of individual DNA-rec-
ognition domains (via protein engineering), multiple 
site-specific guide RNA particles may be used. This 
is a  significant boost in applicability in a variety of 
genome editing experiments. Jinek et al. (2012) [21] 
developed the crRNA (CRISPR RNA) mechanism to 
guide the silencing of invading nucleic acids. The spe-
cific two-RNA chimera directs specific Cas9 endonu-
cleases to introduce double-stranded breaks in target 
DNA, e.g. the Cas9 HNH nuclease domain cleaves the 
complementary strand, whereas the Cas9 RuvC-like 
domain cleaves the noncomplementary strand. Their 
study highlights the potential to exploit the CRISPR-
Cas system for RNA-programmable genome editing.
Generally, the challenge in CRISPR-Cas genome 
editing technologies is engineering highly specific and 
programmable nucleases that generate DNA double-
strand breaks (DSBs) and supervision over the induced 
DNA repair pathways. One of them is the nonhomolo-
gous end-joining (NHEJ) repair pathway, which is an 
error-prone process and often causes random dele-
tion or insertion [51]. It turned out to be a faster and 
highly efficient (up to 80%) process in comparison 
to traditional homologous recombination (HR), use-
ful especially for the generation of knock-out mutants 
[52, 53]. The DSBs induced by CRISPR-Cas can be 
repaired also through the homology-directed-repair 
(HDR) pathway which is also more effective than the 
traditional HR technique and more precise than NHEJ. 
Gene editing using the CRISPR-Cas system with HDR 
recombination between genomic and homologous 
exogenous DNA is a tremendous opportunity for gene 
correction therapy, however, the simultaneous sup-
pressing of NHEJ response, which generates harmful 
byproducts, remains a challenge for researchers [54]. 
Another unresolved disruption for the application of 
the CRISPR-Cas in genome editing is the risk of off-
target cuts due to tolerance of gRNA to mismatched 
DNA [38, 55]. This is a serious problem for the applica-
tion of this technology in gene therapy because of the 
poor knowledge about the consequences of off-target 
genome editing [56]. Here, bioinformatics specialists 
have a  lot to do and intensive research is underway 
to develop appropriate bioinformatic tools to identify 
potential off-target sites or design the most specific 
gRNAs and other components of the CRISPR-tool [57]. 
Currently, there is intense research performed on Cas9 
nuclease manipulation to increase the specificity of this 
technology. These modifications include, for example, 
temporary expression of the nuclease [58] and also the 
application of modified nSpCas9 (nCas9) protein with 
its own sgRNA, which cuts a single strand through the 
inactivation of the nuclease domain RuvC or HNH 
[59], or the mitigating of the helicase activity (eSpCas9) 
[60]. Another modification includes the fusing of the 
nuclease Fok1 with the dead SpCas9 (dSpCas9) which 
has inactivated HNH and RuvC domains [61], or 
(tested on mice models) the binary system Split-SpCas9 
that uses the expression of the nuclease lobe and the 
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α-helical domain independently, where modified gRNA 
abolishes the Cas9 activity and divides the dimer [62]. 
Scientists are also looking for alternative solutions in 
newly discovered nucleases (e.g. SaCas9, St1Cas9, or 
NmCas9) encoded by other cas genes, which could be 
easier packed into viral vectors due to their smaller size 
[59]. Brand-new enzymes like Cpf1 with shorter crRNA 
sequences or C2c2 (Cas13a) and C2c6 (Cas13b) cleav-
ing RNA also aspire to be better substitutes of SpCas9 
in CRISPR engineering [63, 64].
5.2. Instances of CRISPR-tool strategies
 in medicine
First genome-editing technologies (i.e. zinc fin-
ger proteins (ZFNs) and transcription activator-like 
effector nucleases (TALENs)) are still useful but now 
the CRISPR-Cas9 system is more popular. In particu-
lar, genome-editing endonucleases have significantly 
improved our ability to make precise changes in the 
DNA of eukaryotic cells as well as therapeutic strategies 
against viral infections. The human immunodeficiency 
virus (HIV) remains a major global public health issue, 
with more than 35 million individuals being infected 
worldwide. In the HIV context, CRISPR-Cas9 appli-
cations might go further than current anti-retrovi-
ral therapy. In the case of HIV-1, the product of the 
CXCR4 gene in primary T cells mediates viral entry 
into human CD4+ cells by binding to envelope protein 
gp120. Modifications of CXCR4 may induce resistance 
to HIV-1. When evaluating the therapeutic strategy 
based on CRISPR-Cas9, it is critical to understand that 
not only can HIV be eliminated from latently infected 
cells, but the majority of uninfected cells will become 
resistant to HIV infection too. HIV gene therapy has 
progressed very slowly until recent breakthroughs in 
gene-editing methods using the CRISPR-Cas9 [65]. 
Recently, Dash et al. have demonstrated that CRISPR-
Cas9, used in conjunction with the so-called LASER 
ART (Long Active, Slow-Effective Release Antiviral 
Therapy) successfully eliminated latent HIV-1 reser-
voirs from infected, humanized mice [66]. Although 
important challenges still need to be overcome, it seems 
that a promising pathway to HIV cure has been found. 
The CRISPR-Cas9 seems to be also a viable tool for 
eliminating other viruses that persist post-infection in 
host cells. Promising results have been shown for the 
hepatitis  B virus (HBV). Sakuma et al. used a multi-
plexed CRISPR-Cas9-nuclease and Cas9-nickase vec-
tor system, simultaneously targeting three domains 
in the HBV genome. One of the goals achieved was 
the elimination of HBV DNA from host cells via frag-
mentation. This fact seems crucial because the pres-
ence of stable cccHBV DNA in the liver cells is a major 
obstacle in suppressing HBV infection [67]. The use 
of CRISPR-Cas9 based strategies has shown promising 
results against high-risk human papillomavirus (HPV) 
infection which is directly associated with an increased 
risk of developing cancer in an infected individual. 
Two studies show that CRISPR-Cas9 could be useful 
in HPV-related cancer therapy. This system can cause 
virus degradation and cell line growth inhibition (cer-
vical cancer and anal cancer) [68, 69]. Results showing 
the antiviral potency of the CRISPR-Cas9 strategy have 
also been obtained in studies of viruses like the hepa-
titis C virus (HCV) [68], the Epstein-Barr virus (EBV) 
[69], and the African swine fever virus (ASFV) [70]; the 
latter happens to be a major epidemiological, as well as 
economical issue in Europe nowadays.
The CRISPR-Cas application is important for the 
possible use in gene therapy for monogenic recessive 
disorders due to loss-of-function mutations such as in 
the case of cystic fibrosis (CF) and Duchenne muscular 
dystrophy (DMD). These studies underscored the huge 
potential of the CRISPR-Cas technology for human gene 
therapy. CF is an inherited disease related to a defect in 
the gene coding for the cystic fibrosis transmembrane 
conductance regulator (CFTR). It was found that in 70% 
of CF cases, the deletion of phenylalanine at the 508th 
position on the protein chain had taken place. Using 
cultured primary adult intestinal stem cells derived from 
cystic fibrosis patients, the CFTR locus responsible for 
cystic fibrosis was corrected by homologous recombina-
tion (HR) with available homologous donor templates. 
This resulted in the clonal expansion of organoid cul-
tures (miniature organ-like cell clusters) harboring exact 
genetic change. The authors proved that the corrected 
allele is expressed and fully functional as measured in 
clonally expanded organoids [71]. DMD is a recessive 
X-linked disorder caused by a defective gene coding for 
dystrophin, which afflicts primarily males and affects 
both skeletal and cardiac muscles. In the context of gene 
therapy of DMD, there are a few ongoing studies on the 
mdx mouse model of DMD with a nonsense mutation 
in exon 23, which prematurely terminates protein pro-
duction [72, 73]. They have shown that the Cas9 nucle-
ase is targeted to introns 22 and 23 by two single guide 
RNAs. Generation of double stranded breaks (DSBs) by 
nuclease leads to cutting of the region surrounding the 
mutated exon 23. The distal ends are repaired through 
the non-homologous end joining system (NHEJ). Con-
sequently, the reading frame of the dystrophin gene is 
recovered and protein expression is restored. It was 
established that CRISPR-treated mice showed no phe-
notypic evidence of toxicity [73, 74]. Zhang et al. (2020) 
applied the CRISPR-Cas9 technology to correct diverse 
genetic mutations in animal models of DMD, but the 
high doses of adeno-associated virus (AAV) were a sig-
nificant problem in further clinical application. Their 
recent study on the DMD mouse model demonstrated 
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a 20-fold higher efficiency of this technology by packing 
Cas9 nuclease in single-stranded AAV (ssAAV) and use 
of CRISPR single guide RNAs in self-complementary 
AAV (scAAV). The authors observed a restoration of 
dystrophin expression and improved muscle contractil-
ity in mice [75]. It was shown that the CRISPR-Cas sys-
tem type II can directly correct a genetic defect through 
NHEJ or HR mediated gene editing. This provides 
a proof of concept for a gene correction by homologous 
recombination in stem cells cultured from patients with 
a single-gene hereditary defect.
Standard antimicrobial strategies, such as the use of 
antibiotics, have a non-specific effect, removing sensi-
tive microorganisms, both pathogenic and commensals. 
The development of new antibiotics and antimicrobial 
peptides requires detailed knowledge of the metabo-
lism and physiology of bacteria. Lytic bacteriophages, 
in turn, offer exquisite specificity, but individual bac-
teriophages must be isolated against a specific strain, 
and this requires additional screening to determine 
the degree of specificity [76]. There is evidence that 
CRISPR-Cas systems could be used as a “smart anti-
biotic” acting specifically against particular patho-
genic bacteria and saving natural microbiota [23, 77]. 
In Escherichia coli with expression of the type I-E or 
II-A system, transformation of a plasmid with spac-
ers targeting endogenous genes or a lysogenized bac-
teriophage has led to extremely low recovery of viable 
transformants [78–82]. The method still requires fur-
ther optimization, but offers many possibilities to fight 
multidrug resistant bacteria.
6. Phage response
A response to the CRISPR-Cas system was observed 
for the first time among phages closely related to the 
group of Mu-like phages. Nine anti-CRISPR genes 
in the phage genome were characterized [83, 84]. The 
CRISPR-Cas system can be blocked at the stage of com-
plex formation and recognition of foreign DNA. In 
infected P. aeruginosa, the phage genome contains genes 
acrF2, acrF1, and acrF3 which encode anti-CRISPR 
proteins [84, 85]. Production of anti-CRISPR proteins is 
an excellent example of an “arms race” between phages 
and bacteria, where phages are constantly evolving 
to overcome bacterial defense systems. Anti-CRISPR 
proteins could be used in phage therapy of pathogenic 
strains that express resistance induced by the CRISPR-
Cas system. It is extremely relevant in the case of infec-
tions where phage therapy is the sole solution [85].
The bacterial CRISPR-Cas system targets and 
degrades foreign DNA from all mobile genetic ele-
ments, including plasmids, transposons, and patho-
genicity islands [9, 86]. Similar to phages, successful 
transfer of other mobile genetic elements will depend 
on the inactivation of the CRISPR-Cas systems of par-
ticular bacteria. In Pseudomonas sp., the anti-CRISPR 
protein sequences are found in genome loci that are not 
associated with the CRISPR-Cas region. Such regions 
include several elements that are involved in DNA 
transfer and conjugation [83]. Interestingly, also the 
anti-CRISPR genes in mobile genetic elements may play 
an important role in increasing the virulence of bacte-
rial strains. For example, an anti-CRISPR homolog was 
discovered in an active pathogenicity island of a highly 
virulent P. aeruginosa clinical isolate [87].
The first step of the CRISPR-Cas system operation 
is the adaptation of foreign DNA (spacer) by its inser-
tion into the end of the leader CRISPR sequence and 
duplication of the CRISPR repeat [3, 88]. Considering 
occurrences like cutting, insertion, and duplication of 
DNA fragments, it is highly probable that other mecha-
nisms of DNA metabolism are involved in this system. 
Ivančić-Bace et al. (2015) proved that replication pro-
teins and DNA repair proteins, i.e. DNA polymerase I, 
RecG, and PriA, were required to insert new spacers in 
CRISPR loci [89]. It is not excluded that more proteins 
specific to other important cellular processes can be 
involved in this system.
7. Conclusions
The CRISPR-Cas system is associated with multiple 
functions in bacterial cells, starting from the original 
function of resistance to foreign DNA and ending with 
the regulation of biofilm production. It is also likely 
that some of the spacer sequences are complementary 
to short sequences in the bacterial genome, which may 
have an influence on the regulation of bacterial genes, 
e.g. virulence factors. As a result of the “arms race”, 
phages synthesize anti-CRISPR genes, which could be 
extremely relevant in multi-drug resistant (MDR) bac-
teria therapy. In the last decades, a significant increase 
in the number of MDR strains has been observed, 
not only in hospitals but also in the environment. In 
Europe, the mortality rate caused by such infections is 
as high as 25 000 deaths per year. According to predic-
tions, this number will probably increase in the follow-
ing years. Phage therapy could be an alternative strategy 
against MDR bacteria which can also be equipped with 
the CRISPR-Cas system. Initially, it was proposed that 
the CRISPR-Cas system may be used in genetic modifi-
cation of organisms and, in the future, in gene therapy. 
A wide range of applications for the CRISPR-Cas array 
opens many possibilities for contemporary medicine, 
biotechnology, industry, and environmental protection. 
However, it is still necessary to know all the shades of 
this phenomenon.
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